Author

Terry J. Fry

Children's Hospital ColoradoORCID 0000-0001-8044-5226Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Amanda Novak· 1 shared Christine R. Brzezinski· 1 shared Dimiter Dmitrov· 1 shared Kole DeGolieriD· 1 shared Lillie Leach· 1 shared M. FrancisiD· 1 shared Maki NakayamaiD· 1 shared Mark Eric KohleriD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Amanda Novak

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivPreprintNov 10, 2025

High Precision Peptide-MHC Class I CARs Enhance In Vivo Killing ofTargeted CD8 T Cells to Prevent Type 1 Diabetes in Novel RIP-mOVA Model

M. Francis, Winston Hibler, Michael C. Yarnell…·Maki Nakayama

This paper develops a peptide-MHC Class I CAR platform that enhances in vivo killing of antigen-specific CD8 T cells and prevents type 1 diabetes in a novel RIP-mOVA model.

DOI 10.1101/2025.11.10.687586

mouseproteomics

𝕏 PostBluesky

ImmunologybioRxivPreprintMar 13, 2025

Rational redesign of antigen binding domain improves in vivo efficacy of CD22-CAR T cells

Kole DeGolier, Zachary H. Walsh, Lillie Leach…·Terry J. Fry

This study improves the in vivo efficacy of CD22-targeted CAR T cells by optimizing the balance between binding affinity and tonic signaling through rational redesign of the antigen binding domain.

DOI 10.1101/2025.03.13.643183

humanexperimental assay

𝕏 PostBluesky